Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-α-induced angiogenesis in chick chorioallantoic membrane (CAM)

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 2, 2009, Pages 97-103

  Ayalasomayajula, Surya P ^a,b   Ashton, Paul ^c   Kompella, Uday B ^a,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c pSiMedica Ltd   (United Kingdom)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCINOLONE; GLUCOCORTICOID RECEPTOR; MESSENGER RNA; MIFEPRISTONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; DRUG DERIVATIVE; FLUOCINOLONE ACETONIDE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; ASSAY; CELL PROLIFERATION; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; PIGMENT EPITHELIUM; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; CELL LINE; CHICK EMBRYO; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIUM CELL; METABOLISM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FLUOCINOLONE ACETONIDE; HUMANS; MIFEPRISTONE; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, GLUCOCORTICOID; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68149089755     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0090     Document Type: Article

References (44)

1. Rothova, A. Corticosteroids in uveitis. Ophthalmol. Clin. North. Am. 15:389-394, 2002.
2. Leibowitz, H.M., and Kupferman, A. Antiinflammatory medications. Int. Ophthalmol. Clin. 20:117-134, 1980.
3. Wojnar, R.J., Alpaugh, W.C., and Dzelzkalns, E. Characterization of the anti-inflammatory activity and reduced potential for dermal atrophy of (11 beta, 16 beta)-9-fluoro-1′,2′,3′, 4′-tetrahydro-11,21- dihydroxypregna-1,4-dieno[16,17-b]naph thalene-3, 20-dione hydrate (1 : 1) (SQ 26,490), a topically active corticoid. Arzneimittelforschung. 35:1264-1268, 1985. (Pubitemid 16240628)
4. Gao, H.Y., and Li Wan Po, A. Topical formulations of fluocinolone acetonide. Are creams, gels and ointments bioequivalent and does dilution affect activity? Eur. J. Clin. Pharmacol. 46:71-75, 1994. (Pubitemid 24067592)
5. Jaffe, G.J., Ben-Nun, J., Guo, H., et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 107:2024-2033, 2000. (Pubitemid 30823184)
6. Jaffe, G.J., McCallum, R.M., Branchaud, B., et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology. 112:1192-1198, 2005. (Pubitemid 40916923)
7. Callanan, D.G., Jaffe, G.J., Martin, D.F., et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: Three-year clinical trial results. Arch. Ophthalmol. 126:1191-1201, 2008.
8. Mruthyunjaya, P., Khalatbari, D., Yang, P., et al. Effi cacy of lowrelease- rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch. Ophthalmol. 124:1012-1018, 2006. (Pubitemid 44036324)
9. Pearson, P., Levy, B., and Group, F.A.I.S. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multi-center clinical trial. Invest. Ophthalmol. Vis. Sci. 46:E-Abstract 4673, 2005.
10. Mackensen, F., Heinz, C., Becker, M.D., et al. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: A pilot study. Retina. 28:41-45, 2008.
11. Bhisitkul, R.B. Vascular endothelial growth factor biology: Clinical implications for ocular treatments. Br. J. Ophthalmol. 90:1542-1547, 2006. (Pubitemid 44862578)
12. Bakri, S.J., Larson, T.A., and Edwards, A.O. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch. Clin. Exp. Ophthalmol. 246:779-781, 2008.
13. Amrite, A.C., Ayalasomayajula, S.P., Cheruvu, N.P., et al. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest. Ophthalmol. Vis. Sci. 47:1149-1160, 2006.
14. Takahashi, K., Saishin, Y., Mori, K., et al. Topical nepafenac inhibits ocular neovascularization. Invest. Ophthalmol. Vis. Sci. 44:409-415, 2003. (Pubitemid 36134303)
15. Ozaki, N.K., Beharry, K.D., Nishihara, K.C., et al. Regulation of retinal vascular endothelial growth factor and receptors in rabbits exposed to hyperoxia. Invest. Ophthalmol. Vis. Sci. 43:1546-1557, 2002. (Pubitemid 34462657)
16. Ayalasomayajula, S.P., Kompella, U.B. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin- induced diabetic rat model. Eur. J. Pharmacol. 458:283-289, 2003.
17. Raghava, S., and Kompella, U.B., an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: Implications for the therapy of ocular neovascular disorders. Eur. J. Pharmacol. 568:68-74, 2007. (Pubitemid 46976907)
18. Bandi, N., and Kompella, U.B. Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur. J. Pharmacol. 425:109-116, 2001. (Pubitemid 32739155)
19. Kompella, U.B., Bandi, N., and Ayalasomayajula, S.P. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest. Ophthalmol. Vis. Sci. 44:1192-1201, 2003. (Pubitemid 36297840)
20. Luna, J.D., Chan, C.C., Derevjanik, N.L., et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: Comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1betamediated breakdown. J. Neurosci. Res. 49:268-280, 1997.
21. Deeg, C.A., Altmann, F., Hauck, S.M., et al. Down-regulation of pigment epithelium-derived factor in uveitic lesion associates with focal vascular endothelial growth factor expression and breakdown of the blood-retinal barrier. Proteomics. 7:1540-1548, 2007. (Pubitemid 46775884)
22. Senger, D.R., Van de Water, L., Brown, L.F., et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12:303-324, 1993.
23. Blaauwgeers, H.G., Holtkamp, G.M., Rutten, H., et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am. J. Pathol. 155:421-428, 1999. (Pubitemid 29370392)
24. Aukunuru, J.V., Sunkara, G., Ayalasomayajula, S.P., et al. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm. Res. 19:278-285, 2002. (Pubitemid 34211844)
25. Ayalasomayajula, S.P., and Kompella, U.B. Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. Eur. J. Pharmacol. 449:213-220, 2002.
26. Maumenee, A.E. Clinical entities in "uveitis." An approach to the study of intraocular inflammation. Am. J. Ophthalmol. 69:1-27, 1970.
27. Fine, H.F., Baffi, J., Reed, G.F., et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am. J. Ophthalmol. 132:794-796, 2001. (Pubitemid 33031303)
28. Vinores, S.A., Youssri, A.I., Luna, J.D., et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol. Histopathol. 12:99-109, 1997. (Pubitemid 27106924)
29. Vinores, S.A., Derevjanik, N.L., Ozaki, H., et al. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc. Ophthalmol. 97:217-228, 1999. (Pubitemid 30410092)
30. Ferrara, N., Carver-Moore, K., Chen, H., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:439-442, 1996. (Pubitemid 26102720)
31. Carmeliet, P., Ferreira, V., Breier, G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:435-439, 1996. (Pubitemid 26102719)
32. Witmer, A.N., Blaauwgeers, H.G., Weich, H.A., et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest. Ophthalmol. Vis. Sci. 43:849-857, 2002.
33. Husain, D., Ambati, B., Adamis, A.P., et al. Mechanisms of age-related macular degeneration. Ophthalmol. Clin. North Am. 15:87-91, 2002.
34. Campochiaro, P.A., Soloway, P., Ryan, S.J., et al. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol. Vis. 5:34, 1999.
35. Ablonczy, Z., and Crosson, C.E. VEGF modulation of retinal pigment epithelium resistance. Exp. Eye Res. 85:762-771, 2007. (Pubitemid 350166363)
36. Joussen, A.M., Poulaki, V., Tsujikawa, A., et al. Suppression of diabetic retinopathy with angiopoietin-1. Am. J. Pathol. 160:1683-1693, 2002.
37. Frank, R.N. Growth factors in age-related macular degeneration: Pathogenic and therapeutic implications. Ophthalmic Res. 29:341-353, 1997. (Pubitemid 27427367)
38. Stellato, C., Schwiebert, L.M., and Schleimer, R.P. Mechanisms of glucocorticosteroid action. In: Barnes, P.J., Grunstein, M.M., Leff, A.R., et al., eds. Asthma. Philadelphia: Lippincott-Raven; 1569-1596, 1997.
39. Ferrara, N., and Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 18:4-25, 1997. (Pubitemid 27076453)
40. Kaven, C.W., Spraul, C.W., Zavazava, N.K., et al. Growth factor combinations modulate human retinal pigment epithelial cell proliferation. Curr. Eye Res. 20:480-487, 2000.
41. Auerbach, R., Akhtar, N., Lewis, R.L., et al. Angiogenesis assays: Problems and pitfalls. Cancer Metastasis Rev. 19:167-172, 2000.
42. Sheu, J.R., Yen, M.H., Kan, Y.C., et al. Inhibition of angiogenesis in vitro and in vivo: Comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v) beta3 integrin monoclonal antibody. Biochim. Biophys. Acta. 1336:445-454, 1997.
43. Sheu, J.R., Fu, C.C., Tsai, M.L., et al. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res. 18:4435-4441, 1998.
44. Baud, V., and Karin, M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11:372-377, 2001. (Pubitemid 32900529)